
April 3 (Reuters) - Sangamo Therapeutics Inc SGMO.O:
SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM
SANGAMO THERAPEUTICS INC: SANGAMO TO RECEIVE AN $18 MILLION UPFRONT LICENSE FEE
SANGAMO THERAPEUTICS INC: ELIGIBLE TO EARN UP TO $1.4 BILLION IN ADDITIONAL LICENSED TARGET FEES AND MILESTONE PAYMENTS
SANGAMO: AGREEMENT GRANTS LILLY RIGHTS TO EMPLOY CO'S NOVEL PROPRIETARY CAPSID, STAC-BBB, FOR UP TO 5 POTENTIAL DISEASE TARGETS